Foghorn Therapeutics (FHTX) Revenue & Revenue Breakdown
Foghorn Therapeutics Revenue Highlights
Latest Revenue (Y)
$30.91M
Latest Revenue (Q)
$3.27M
Foghorn Therapeutics Revenue by Period
Foghorn Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $30.91M | 36.75% |
| 2024-12-31 | $22.60M | -33.83% |
| 2023-12-31 | $34.16M | 77.63% |
| 2022-12-31 | $19.23M | 1357.77% |
| 2021-12-31 | $1.32M | 206.74% |
| 2020-12-31 | $430.00K | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Foghorn Therapeutics generated $30.91M in revenue during NA 2025, up 36.75% compared to the previous quarter, and up 7188.14% compared to the same period a year ago.
Foghorn Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-03-31 | $3.27M | -64.67% |
| 2025-12-31 | $9.25M | 13.42% |
| 2025-09-30 | $8.15M | 7.89% |
| 2025-06-30 | $7.56M | 26.97% |
| 2025-03-31 | $5.95M | 108.40% |
| 2024-12-31 | $2.86M | -63.42% |
| 2024-09-30 | $7.81M | 13.36% |
| 2024-06-30 | $6.89M | 36.40% |
| 2024-03-31 | $5.05M | -12.46% |
| 2023-12-31 | $5.77M | -66.99% |
| 2023-09-30 | $17.48M | 212.16% |
| 2023-06-30 | $5.60M | 5.46% |
| 2023-03-31 | $5.31M | 26.89% |
| 2022-12-31 | $4.18M | -36.93% |
| 2022-09-30 | $6.63M | 47.75% |
| 2022-06-30 | $4.49M | 14.54% |
| 2022-03-31 | $3.92M | 449.79% |
| 2021-12-31 | $713.00K | 1639.02% |
| 2021-09-30 | $41.00K | -85.30% |
| 2021-06-30 | $279.00K | -2.45% |
| 2021-03-31 | $286.00K | 13.94% |
| 2020-12-31 | $251.00K | 40.22% |
| 2020-09-30 | $179.00K | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | - |
Foghorn Therapeutics generated $3.27M in revenue during Q1 2026, up -64.67% compared to the previous quarter, and up 114.39% compared to the same period a year ago.
Foghorn Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| VNDA | Vanda Pharmaceuticals | $216.10M | $51.72M |
| ARCT | Arcturus Therapeutics | $82.03M | $2.06M |
| ENTA | Enanta Pharmaceuticals | $65.32M | $17.16M |
| FHTX | Foghorn Therapeutics | $30.91M | $3.27M |
| TRDA | Entrada Therapeutics | $25.42M | $875.00K |
| PYXS | Pyxis Oncology | $13.86M | - |
| HUMA | Humacyte | $2.04M | $495.00K |
| IMRX | Immuneering | - | - |
| ZURA | Zura Bio | - | - |
| ASMB | Assembly Biosciences | - | - |
| SGMT | Sagimet Biosciences | - | - |